Why Inflammation is a Useful Target for “Triggered” Release
Designing Stimuli-Responsive Nanoparticles for Diseases
Future Directions
References
Conventional drug delivery is fraught with limitations. Targeted delivery is a hot button issue in modern medicine, with developers exploring many avenues for more precise treatments. Stimuli-responsive nanomaterials (SR-NPs) are a great example of this collective effort.
Image Credit: PanuShot/Shutterstock.com
SR-NPs are novel drug delivery systems that respond to internal or external triggers (like pH, redox potential, enzymes, temperature, light, or magnetic fields). This allows drug release to be biased towards a target site and timed to a desired window.
Below, the focus is on common design strategies and response mechanisms that are most relevant to inflammatory and other disease microenvironments.
Saving this article for later? Grab a PDF here.
Why Inflammation is a Useful Target for “Triggered” Release
Acute inflammation recruits macrophages and neutrophils, which generate reduced oxygen species (ROS) and cytokines as part of host defense.1 When inflammation persists, becoming chronic, the tissue environment often shifts in ways that are chemically actionable for drug delivery: lower pH, higher oxidative stress, hypoxia, and upregulated enzymes.2 These cues show up across chronic conditions like arthritis, vascular inflammation, IBD, and some cancers.3
These features (pH, ROS, hypoxia, and enzyme activity) can thus be used as triggers for drug release, with the goal of improving local efficacy while reducing off-target exposure.
Designing Stimuli-Responsive Nanoparticles for Diseases
Researchers have designed SR-NPs that respond to distinct features of diseased cells, including acidic pH, elevated ROS levels, hypoxia, and increased enzymatic activity, to deliver drugs with precision and control to target sites. Exogenous stimuli, including light, magnetic fields, ultrasound, and temperature, can trigger site-specific drug release from SR-NPs.4
To date, scientists have developed several types of stimuli-responsive nanoparticles to treat various diseases. Some of the most prominent types are discussed below.
pH-responsive Nanoparticles
pH-responsive nanoparticles are typically designed using pH-sensitive linkers that break down in acidic environments or with charge-shifting polymers.5 Nanoparticles carrying anti-inflammatory drugs can be engineered to release drugs in inflamed joints, where low pH triggers drug release and reduces immune cell infiltration. This targeted release helps protect tissues and decrease inflammation.
Scientists have also designed pH-responsive nanogels that remain stable in the bloodstream but degrade in acidic tissues. These nanomaterials can safely deliver immune-modulating drugs by changing their structure in response to lower pH and helping control inflammation by targeting specific immune cells.
ROS-responsive Nanoparticles
ROS-responsive nanoparticles are engineered to target inflammatory sites with elevated ROS. For instance, tannic acid-capped hafnium disulfide nanosheets can scavenge ROS and reduce pro-inflammatory cytokine production, offering therapeutic benefits in inflammatory bowel disease (IBD). These nanosheets leverage their large surface area and redox-active properties to efficiently neutralize ROS.
Hypoxia-responsive Nanoparticles
Hypoxia-responsive nanoparticles are designed to sense and respond to low-oxygen environments, enabling tumor therapy.6 For example, mesoporous silica nanoparticles functionalized with azobenzene derivatives and fluorescent dyes can detect hypoxia by emitting fluorescence upon azo bond cleavage. This property enables noninvasive imaging and diagnosis of IBD by highlighting hypoxic regions.
Researchers have also designed hypoxia-responsive hydrogels loaded with anti-inflammatory or neuroprotective drugs for localized treatment of ischemic stroke.
Enzyme-responsive Nanoparticles
Scientists engineer nanoparticles that respond to enzymatic triggers via mechanisms such as altering surface charge, ligand activation, or cleavage of specific chemical bonds. For instance, in atherosclerosis, poly(lactic-co-glycolic acid) (PLGA) nanoparticles featuring cathepsin K-sensitive peptides and arginine-glycine-aspartic acid sequences enable the localized release of rapamycin within diseased plaques, prolonging circulation time and increasing drug accumulation at the target site.
Light-responsive Nanoparticles
Near-infrared (NIR) light can penetrate tissue more effectively than visible light and is often used to trigger release. Light-responsive nanoparticles can be activated by irradiation to begin drug release. NIR-responsive systems - including photothermal absorbers and lanthanide-doped upconversion nanoparticles (UCNPs) - are being developed for controlled delivery, imaging, and theranostics in inflammatory environments.
Magnetic field-responsive Nanoparticles
Magnetic field-responsive nanoparticles incorporate magnetic elements such as iron, cobalt, nickel, or manganese to enable remote manipulation and targeted delivery. Ligand-conjugated iron oxide nanoparticles serve as contrast agents for imaging atherosclerosis and myocardial infarction.
Ultrasound-responsive Nanoparticles
Ultrasound enhances tissue penetration, increases cellular uptake by transiently permeabilizing cell membranes, and facilitates intracytoplasmic drug delivery. Ultrasound-responsive nanoparticles enable controlled drug release and imaging through mechanisms such as activation, mechanical disruption, and localized heating induced by ultrasonic waves.
Temperature-responsive Nanoparticles
Temperature-responsive nanoparticles exploit higher temperatures at inflamed sites to trigger local drug release. Temperature-responsive copolymers can be incorporated to impart thermotactic behavior, enabling nanoparticles to remain stable at physiological temperature but release drugs when exposed to temperatures above normal body temperature. Thermoresponsive nanospheres composed of cross-linked Pluronic F127, chitosan oligosaccharide, and kartogenin have been used to deliver diclofenac for the treatment of osteoarthritis.
Interested in other benefits to nanomedicine? Read this article >
Future Directions
The biggest translation challenges are usually not “more clever triggers,” but manufacturing reproducibility, standardized characterization, and credible safety packages (including long-term fate and toxicity). SR-NPs will move faster clinically when papers report not only proof-of-concept release, but also stability, batch consistency, and clear benefit over simpler formulations.
Ongoing research is advancing the engineering of SR-NPs to achieve higher specificity, multifunctionality, controlled release profiles, and improved biocompatibility. Looking ahead, the field is shifting toward the clinical translation of SR-NPs, underscoring the need for scalable, reproducible manufacturing processes and rigorous safety and efficacy evaluation.
Regulatory approval remains a significant hurdle, requiring standardized characterization, long-term toxicity studies, and robust quality control. By leveraging advances in materials science, nanotechnology, and biomedical engineering, SR-NPs are poised to play a central role in next-generation therapies for inflammatory diseases and beyond.
References
- Hirayama D, Iida T, Nakase H. The Phagocytic Function of Macrophage-Enforcing Innate Immunity and Tissue Homeostasis. Int J Mol Sci. 2017;19(1):92. doi: 10.3390/ijms19010092.
- Qian X, et al. Acidosis regulates immune progression in rheumatoid arthritis by promoting the expression of cytokines and co-stimulatory molecules in synovial fibroblasts. Mol Med. 2025;31(1):136. doi: 10.1186/s10020-025-01181-x.
- Chavda VP, Feehan J, Apostolopoulos V. Inflammation: The Cause of All Diseases. Cells. 2024;13(22):1906. doi: 10.3390/cells13221906.
- Yang J, des Rieux A, Malfanti A. Stimuli-Responsive Nanomedicines for the Treatment of Non-cancer Related Inflammatory Diseases. ACS Nano. 2025;19(16):15189-15219. doi: 10.1021/acsnano.5c00700.
- Nunziata G, et al. Smart pH-Responsive polymers in biomedical Applications: Nanoparticles, hydrogels, and emerging hybrid platforms. Mater Today Chem. 2025;49, 103063. https://doi.org/10.1016/j.mtchem.2025.103063
- Zhang Y, et al. Hypoxia-responsive nanoparticles for fluorescence diagnosis and therapy of cancer. Theranostics. 2025;15(4):1353-1375. doi: 10.7150/thno.104190.
Disclaimer: The views expressed here are those of the author expressed in their private capacity and do not necessarily represent the views of AZoM.com Limited T/A AZoNetwork the owner and operator of this website. This disclaimer forms part of the Terms and conditions of use of this website.